Fiche publication
Date publication
octobre 1993
Journal
Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
,
Dr GEOFFROIS Lionnel
,
Dr LUPORSI Elisabeth
,
Dr SPAETH Dominique
Tous les auteurs :
Conroy T, Geoffrois L, Guillemin F, Luporsi E, Krakowski I, Spaëth D, Frasie V, Volff D
Lien Pubmed
Résumé
Numerous preclinical and clinical trials showed that circadian-modified 5-fluoro-2-deoxyuridine (floxuridine; FUdR) infusion administered with a totally implantable programmable pump is associated with lower toxicity, higher dose intensity, and improved therapeutic outcome in renal cell carcinoma (RCC).
Mots clés
Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, drug therapy, Circadian Rhythm, Drug Administration Schedule, Female, Floxuridine, administration & dosage, Humans, Infusion Pumps, Infusions, Intravenous, Kidney Neoplasms, drug therapy, Male, Middle Aged, Neoplasm Metastasis, Treatment Outcome
Référence
Cancer. 1993 Oct;72(7):2190-7
